...
首页> 外文期刊>Hematology/Oncology Clinics of North America >Hepatic resection for gastrointestinal stromal tumor liver metastases.
【24h】

Hepatic resection for gastrointestinal stromal tumor liver metastases.

机译:肝切除适用于胃肠道间质瘤的肝转移。

获取原文
获取原文并翻译 | 示例
           

摘要

Liver resection is the preferred treatment for gastrointestinal stromal tumor liver metastases (GIST LMs) when complete resection can be achieved. Major and extended hepatic resections can be safely performed, and using modern techniques, an increasing proportion of patients with GIST LMs are candidates for potentially curative therapy. The combination of tyrosine kinase inhibitor therapy (eg, imatinib) with surgery seems to improve outcome, and although prospective data are lacking, a short neoadjuvant course (6 months) of imatinib therapy followed by resection may improve patient selection for surgery and outcome from treatment. Postoperative therapy with imatinib is generally advised, although the duration of such therapy is not yet clearly defined. These questions may formulate the basis for future prospective studies of imatinib with complete resection of GIST LMs.
机译:当可以完全切除时,肝切除是胃肠道间质瘤肝转移(GIST LM)的首选治疗方法。可以安全地进行大范围和大范围的肝切除术,并且使用现代技术,越来越多的GIST LM患者成为潜在治疗方法的候选人。酪氨酸激酶抑制剂治疗(例如伊马替尼)与手术相结合似乎可以改善预后,尽管尚缺乏前瞻性数据,但伊马替尼治疗的新辅助疗程短(6个月),然后再切除可能会改善患者的手术选择和治疗结果。通常建议使用伊马替尼进行术后治疗,尽管这种治疗的持续时间尚未明确。这些问题可以为伊马替尼在完全切除GIST LM的基础上进行未来前瞻性研究奠定基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号